Terms: = Ovarian cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A
2255 results:
1. Analysis of the nischarin expression across human tumor types reveals its context-dependent role and a potential as a target for drug repurposing in oncology.
Ostojić M; Đurić A; Živić K; Grahovac J
PLoS One; 2024; 19(5):e0299685. PubMed ID: 38781180
[TBL] [Abstract] [Full Text] [Related]
2. Construction and Validation of a Nomogram to Predict the Postoperative Venous Thromboembolism Risk in Patients with HGSOC.
Huang Z; Li L; Gong Z; Tang L
Clin Appl Thromb Hemost; 2024; 30():10760296241255958. PubMed ID: 38767088
[TBL] [Abstract] [Full Text] [Related]
3. Validating the 2023 FIGO staging system: A nomogram for endometrioid endometrial cancer and adenocarcinoma.
Feng Y; Miao F; Li Y; Li M; Cao Y
Cancer Med; 2024 May; 13(10):e7216. PubMed ID: 38752451
[TBL] [Abstract] [Full Text] [Related]
4. An extensive analysis of the prognostic and immune role of FOXO1 in various types of cancer.
Li J; Wang C; Xu X; Chen J; Guo H
Braz J Med Biol Res; 2024; 57():e13378. PubMed ID: 38716982
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer.
Yu D; Luo Y; Guo R; Ma F; Chang Y; Dang J
J Gene Med; 2024 May; 26(5):e3686. PubMed ID: 38689382
[TBL] [Abstract] [Full Text] [Related]
6. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract] [Full Text] [Related]
7. Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
Dhar C; Ramachandran P; Xu G; Pickering C; Čaval T; Wong M; Rice R; Zhou B; Srinivasan A; Aiyetan P; Chu CW; Moser K; Herzog TJ; Olawaiye AB; Jacob F; Serie D; Lindpaintner K; Schwarz F
Br J Cancer; 2024 Jun; 130(10):1716-1724. PubMed ID: 38658783
[TBL] [Abstract] [Full Text] [Related]
8. Ultrasound-based deep learning radiomics model for differentiating benign, borderline, and malignant ovarian tumours: a multi-class classification exploratory study.
Du Y; Guo W; Xiao Y; Chen H; Yao J; Wu J
BMC Med Imaging; 2024 Apr; 24(1):89. PubMed ID: 38622546
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.
Sun W; Xu P; Gao K; Lian W; Sun X
J Cell Mol Med; 2024 Apr; 28(8):e18309. PubMed ID: 38613345
[TBL] [Abstract] [Full Text] [Related]
10. Human epididymis protein 4: Analysis of national health and nutrition examination survey data.
Penick ER; Beltran TA; Choi YS; Wilson KL
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():86-90. PubMed ID: 38598900
[TBL] [Abstract] [Full Text] [Related]
11. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract] [Full Text] [Related]
12. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
13. Patient-reported outcome measures (PROMs) to personalise follow-up care of ovarian cancer: what do patients think? A qualitative interview study.
Seeratan DD; van Schuylenburch RG; van Lonkhuijzen LRCW; Aarts JWM
Support Care Cancer; 2024 Mar; 32(4):247. PubMed ID: 38528152
[TBL] [Abstract] [Full Text] [Related]
14. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic and immunotherapeutic potential of regulatory T cell-associated signature in ovarian cancer.
Liu Y; Shan F; Sun Y; Kai H; Cao Y; Huang M; Liu J; Zhang P; Zheng Y
J Cell Mol Med; 2024 Apr; 28(8):e18248. PubMed ID: 38520220
[TBL] [Abstract] [Full Text] [Related]
16. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
Xiong J; Liang H; Sun X; Gao K
J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
[TBL] [Abstract] [Full Text] [Related]
17. [Preparation and characterization of chicken anti-human B7-H4 IgY polyclonal antibody].
Zhang L; Fan Z; Zhang W; Huang H; Wang J; Hei A; Cong Y; Xu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):257-266. PubMed ID: 38512036
[TBL] [Abstract] [Full Text] [Related]
18. Identification of prognostic factors and construction of nomogram to predict cancer-specific survival for patients with ovarian granulosa cell tumors.
Zhang Y; Zhang Z; Ding X; Zhang K; Dai Y; Cheng W; Luo C
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2046. PubMed ID: 38507268
[TBL] [Abstract] [Full Text] [Related]
19. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract] [Full Text] [Related]
20. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
Vyhlídalová Kotrbová A; Gömöryová K; Mikulová A; Plešingerová H; Sladeček S; Kravec M; Hrachovinová Š; Potěšil D; Dunsmore G; Blériot C; Bied M; Kotouček J; Bednaříková M; Hausnerová J; Minář L; Crha I; Felsinger M; Zdráhal Z; Ginhoux F; Weinberger V; Bryja V; Pospíchalová V
J Extracell Vesicles; 2024 Mar; 13(3):e12420. PubMed ID: 38490958
[TBL] [Abstract] [Full Text] [Related]
[Next]
